scholarly journals Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome

2019 ◽  
Vol 5 (4) ◽  
pp. 20190064
Author(s):  
Antonino Cattafi ◽  
Mariacarmela Santarpia ◽  
Martina Francesca Micalizzi ◽  
Carmelo Sofia ◽  
Elvira Condorelli ◽  
...  
Keyword(s):  
Medical Oncology ◽  
The Body ◽  
Skeletal Structure ◽  
Unknown Primary ◽  
Breast Cancers ◽  
Cup Syndrome ◽  
Carcinoma Of Unknown Primary ◽  
Node Metastases ◽  
Vertebral Bodies ◽  
Oncology Unit

Cancer of unknown provenance is a rare disease, accounting approximately for up to 1% of all breast cancers. A 68-year-old female was admitted to the Medical Oncology Unit of Policlinico Universitario G.Martino because of diffused bone-involvement, with mixed (osteolytic/osteoblastic) features, which interested almost every skeletal structure of the body (vertebral bodies of the entire column, costal skeleton, sternum, proximal third of both humeri, scapulae, clavicles, pelvis and femurs), suspicious for metastatic disease.

scholarly journals Metastases from Occult Breast Cancer: A Case Report of Carcinoma of Unknown Primary Syndrome

2020 ◽  
Vol 13 (3) ◽  
pp. 1158-1163
Author(s):  
Erika Barbieri ◽  
Chiara Annunziata Pasqualina Anghelone ◽  
Damiano Gentile ◽  
Carlotta La Raja ◽  
Alberto Bottini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Breast Tumor ◽  
Unknown Primary ◽  
Breast Cancers ◽  
Cup Syndrome ◽  
Occult Breast Cancer ◽  
Carcinoma Of Unknown Primary ◽  
Patient Reported ◽  
Immunohistochemical Analyses ◽  
Radiological Examinations

Carcinoma of unknown primary (CUP) syndrome occurs when metastases from an unknown primary site spread to multiple organs. Occult breast cancer (OBC) is defined as a clinically recognizable metastatic carcinoma from an undetectable primary breast tumor. It accounts for 0.3–1% of all breast cancers, often presenting with lymph node, bone, and skin metastases. Clinical and radiological examinations represent the first steps in the diagnostic algorithm for CUP syndrome from OBC. However, histological and immunohistochemical analyses, multidisciplinary team evaluation, and a multidisciplinary therapy are essential in the diagnosis and treatment of CUP syndrome from OBC. We report the case of a 52-year-old woman who underwent the removal of a parietal skin lesion. The histological and immunohistochemical analyses suggested a breast cancer origin. Clinical assessment and laboratory and radiological examinations did not locate the primary tumor. Hormone therapy was offered to the patient; however, she refused it. After 28 months, the patient reported a right cervical lump, and a total-body positron emission tomography showed dissemination of the disease to the lymph nodes and bone. A CUP syndrome from OBC was diagnosed. A multimodality approach with radiotherapy and hormone and biological therapy was started. At present, 5 years from the first presentation, the patient is asymptomatic despite the disseminated disease.

Adenosquamous carcinoma of unknown primary origin: a case report and literature review

2015 ◽  
Vol 129 (S2) ◽  
pp. S91-S94 ◽  
Author(s):  
T Takeuchi ◽  
T Yasui ◽  
M Izeki ◽  
S Komune
Keyword(s):  
Semicircular Canal ◽  
Rare Case ◽  
Adenosquamous Carcinoma ◽  
Unknown Primary ◽  
Pertinent Literature ◽  
Carcinoma Of Unknown Primary ◽  
Node Metastases ◽  
Primary Origin ◽  
Additional Therapy ◽  
Unknown Primary Origin

AbstractBackground:Adenosquamous carcinoma is a rare variant of semicircular canal that can affect various regions, including the head and neck. Adenosquamous carcinoma is characterised pathologically by the simultaneous presence of distinct areas of semicircular canal and adenocarcinoma, and usually takes an aggressive course with local recurrences, early lymph node metastases and distant disseminations.Case:We report a rare case of neck adenosquamous carcinoma of unknown primary origin, which was well-controlled by thorough resection without any other additional therapy.Conclusion:We discuss the diagnosis and treatment of adenosquamous carcinoma along with a review of pertinent literature. We also consider the potential differential diagnosis of branchiogenic carcinoma.

scholarly journals Testicular Metastatic Sarcomatoid Carcinoma of Unknown Primary: A Case Report

2020 ◽  
Vol 06 (03) ◽  
pp. E62-E65
Author(s):  
Leo Nygaard ◽  
Søren Rafael Rafaelsen ◽  
Jan Lindebjerg ◽  
Malene Roland Vils Pedersen
Keyword(s):  
Case Report ◽  
Sarcomatoid Carcinoma ◽  
Unknown Primary ◽  
Carcinoma Of Unknown Primary

scholarly journals Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report

2021 ◽  
Vol 28 (3) ◽  
pp. 1938-1945
Author(s):  
Keiji Sugiyama ◽  
Ai Izumika ◽  
Akari Iwakoshi ◽  
Riko Nishibori ◽  
Mariko Sato ◽  
...  
Keyword(s):  
Lymph Node ◽  
Cervical Lymph Node ◽  
Kinase Inhibitors ◽  
Fusion Gene ◽  
Liver Lesion ◽  
Lymph Node Biopsy ◽  
Unknown Primary ◽  
Carcinoma Of Unknown Primary ◽  
Anaplastic Lymphoma ◽  
Lymph Node Swelling

Gene alteration in anaplastic lymphoma kinase (ALK) is rare, and the efficacy of ALK inhibitors in the treatment of carcinoma of unknown primary (CUP) with ALK alteration remains unclear. The patient was a 56-year-old woman who presented with cervical lymph node swelling. Computed tomography revealed paraaortic, perigastric, and cervical lymph node swelling; ascites; a liver lesion; and a left adrenal mass. A cervical lymph node biopsy was performed, and pathological diagnosis of an undifferentiated malignant tumor was conducted. Finally, the patient was diagnosed with CUP and treated with chemotherapy. To evaluate actionable mutations, we performed a multigene analysis, using a next-generation sequencer (FoundationOne® CDx). It revealed that the tumor harbored an echinoderm microtubule-associated protein-like 4 (EML4) and ALK fusion gene. Additionally, immunohistochemistry confirmed ALK protein expression. Alectinib, a potent ALK inhibitor, was recommended for the patient at a molecular oncology conference at our institution. Accordingly, alectinib (600 mg/day) was administered, and the multiple lesions and symptoms rapidly diminished without apparent toxicity. The administration of alectinib continued for a period of 10 months without disease progression. Thus, ALK-tyrosine kinase inhibitors should be considered in patients with CUP harboring the EML4-ALK fusion gene.

scholarly journals Carcinoma of Unknown Primary and the 8th Edition TNM Classification for Head and Neck Cancer

2021 ◽  
Author(s):  
Robert Boeker ◽  
Carmen Stromberger ◽  
Max Heiland ◽  
Benedicta Beck‐Broichsitter ◽  
Veit M. Hofmann ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Tnm Classification ◽  
Unknown Primary ◽  
Carcinoma Of Unknown Primary ◽  
8Th Edition
Sign in / Sign up

Export Citation Format

Share Document